EMERGENT BIOSOLUTIONS INC. lobbying for EMERGENT BIOSOLUTIONS INC

Filing · LD-2 quarterly report Q2 report

Reporting period

2nd Quarter 2025

Apr 1 - June 30 · Posted Jul 16, 2025

Expenses

$440,000

What this organization spent lobbying with its own staff. Reported using IRS section 162(e) definitions (method C): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

District of Columbia

Official filing document

Government bodies contacted 5

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 4

Homeland Security

- Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act - Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY25 and FY26 - Opioid crisis legislation, naloxone access and awareness - State opioid response (SOR) Grant funding FY25 and FY26 - Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY25 and FY26 - Tribal Opioid Response Grant funding for FY26 - NDAA for Fiscal Year 2025 and Fiscal Year 2026 - provisions related to biological and chemical defense and access to naloxone - H.R.1968, the Full-Year Continuing Appropriations and Extensions Act, 2025

Disaster Planning/Emergencies

- Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act - Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY25 and FY26 - Opioid crisis legislation, naloxone access and awareness - State opioid response (SOR) Grant funding FY25 and FY26 - Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY25 and FY26 - Tribal Opioid Response Grant funding for FY26 - NDAA for Fiscal Year 2025 and Fiscal Year 2026 - provisions related to biological and chemical defense and access to naloxone - H.R.1968, the Full-Year Continuing Appropriations and Extensions Act, 2025

Budget/Appropriations

- Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act - Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY25 and FY26 - Opioid crisis legislation, naloxone access and awareness - State opioid response (SOR) Grant funding FY25 and FY26 - Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY25 and FY26 - Tribal Opioid Response Grant funding for FY26 - NDAA for Fiscal Year 2025 and Fiscal Year 2026 - provisions related to biological and chemical defense and access to naloxone - H.R.1968, the Full-Year Continuing Appropriations and Extensions Act, 2025

Health Issues

- Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act - Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY25 and FY26 - Opioid crisis legislation, naloxone access and awareness - State opioid response (SOR) Grant funding FY25 and FY26 - Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY25 and FY26 - Tribal Opioid Response Grant funding for FY26 - NDAA for Fiscal Year 2025 and Fiscal Year 2026 - provisions related to biological and chemical defense and access to naloxone - H.R.1968, the Full-Year Continuing Appropriations and Extensions Act, 2025

Bills named in this filing 1

H.R. 1968
Full-Year Continuing Appropriations and Extensions Act, 2025